

The logo for Roadmap, consisting of three overlapping, curved bands in shades of orange, purple, and pink.

# ROADMAP

## Data Cube


*28<sup>th</sup> Alzheimer Europe Conference  
Barcelona 29<sup>th</sup>– 31<sup>st</sup> October 2018*

[www.roadmap-alzheimer.org](http://www.roadmap-alzheimer.org)

# Development the ROADMAP Data Cube

Glòria Garcia, Carlos Díaz | SYNAPSE | 31<sup>st</sup> October 2018

A 'heatmap' that would allow the visualization of:



**Alzheimer's Disease outcomes**

VS.

**Existent data sources**

VS.

**Relevance to disease stage**


# Data Cube

## WP2: Alzheimer's Disease Outcomes definition

### 148 Alzheimer's Disease Outcomes

Gathered from:

- Literature Review (Pragmatic & Systematic)
- Consultation with working groups
- Survey shared among people with dementia, carers and health professionals
- Refined with feedback from data sources





# Data Cube

WP3: Data source population

## 77 European data sources

Including:

- Electronic Health Records
- Alzheimer's disease cohorts
- Clinical trials



# Data Cube


## Data Sources vs. AD-Outcomes




# Data Cube

## WP2: AD-Outcomes prioritization per stakeholders


People with dementia



Carers




Health professionals



# Data Cube

WP2: Outcomes relevant to disease stage



**Mild  
Cognitive  
Impairment**

**Mild  
Dementia**

**Moderate  
to Severe  
Dementia**

## Relevance scale according to:

- Systematic Literature Review
- Survey shared among people with dementia, carers and health professionals
- Patient-public involvement



# Data Cube

## AD-Stages vs. AD-Outcomes



# Data Cube

## AD-Stages vs. Data Sources

### AD Outcomes' Relevance within the AD-Stages



3 = ✓✓  
 2 = ✓  
 1 = --

### AD-Outcomes availability within the Data Sources

5 = Yes, directly  
 4 = Yes, indirectly  
 3 = Yes, partially  
 2 = We can access to this information via other sources  
 1 = No  
 0 = "Empty"

ROADMAP LIST OF OUTCOMES - RELEVANCE OF OUTCOMES TO DISEASE STAGE


	Relevance provided by WP2			Availability				
	MCI	Mild Deme	Mode rate	MCI	Mild Deme	Mod erate		
	All evidence	All evidence	All evidence	All evidence	All evidence	All evidence		
Subjective Memory Complaint	1	1	1	No	1	1	1	
Subjective Cognitive Complaint	1	1	1	No	1	1	1	
Mild Cognitive Impairment (MCI)	1	1	1	No	1	1	1	
Amnesic MCI (aMCI)	1	1	1	No	1	1	1	
Non-amnesic MCI (naMCI)	1	1	1	No	1	1	1	
Dementia	1	1	1	No	1	1	1	
Alzheimer's disease	1	1	1	Yes, directly	5	5	5	
Prodromal AD (pAD)	1	1	1	No	1	1	1	
Preclinical AD	1	1	1	No	1	1	1	
Vascular dementia	1	1	1	No	1	1	1	
Mixed dementia	1	1	1	No	1	1	1	
Frontotemporal dementia	1	1	1	No	1	1	1	
Dementia with Lewy bodies	1	1	1	No	1	1	1	
Dementia in other diseases classified elsewhere	1	1	1	No	1	1	1	
Staging severity of dementia	1	1	1	Yes, directly	5	5	5	
Global improvement/stability/decline	1	2	1	Yes, directly	5	10	5	
Memory	3	3	1	Yes, indirect	4	12	4	
Language and communication	3	2	1	Yes, indirect	4	12	4	
Visuospatial ability	1	1	1	Yes, indirect	4	4	4	
Attention/Executive functions	2	3	1	Yes, indirect	4	8	12	4
Intelligence	1	1	1	No	1	1	1	
Getting lost in own home	1	1	2	No	1	1	2	
Not recognising family	1	1	3	No	1	1	3	


	MCI	Mild Dementia	Moderate Severe Dementia
LFAN	539	564	469
LFBC	539	564	469
LZAM	541	566	471
LZAN	541	566	471
IPCI	400	411	354
AUH	395	410	355
SIDIAP	552	571	484
SIDIGI	550	569	482
ReDeGi	344	357	305
CaPS	561	576	477
CFAS	556	579	500
CFASII	590	613	526
ELSA	638	649	530
ICICLE_PD	474	477	410
Whitehall_II	597	616	501
CamPaLGN			

# Data Cube

## AD-Stages vs. Data Sources



# Data Cube Acknowledgement



## ROADMAP PARTNERS

### ACADEMIA



### EFPIA



### REGULATORY AGENCIES



### SMEs



### PATIENT ORGANISATION



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.